valeant pharmaceuticals inte (VRX) Key Developments
Valeant Pharmaceuticals International Mulls Acquisitions
May 20 15
Valeant Pharmaceuticals International, Inc. (TSX:VRX) is seeking acquisitions.
Valeant Pharmaceuticals International, Inc. - Shareholder/Analyst Call
May 12 15
Annual Meeting of Shareholders
Valeant Pharmaceuticals International, Inc. Announces Management Changes
Apr 29 15
On April 29, 2015, Valeant Pharmaceuticals International, Inc. announced that Howard B. Schiller intends to resign as Executive Vice President and Chief Financial Officer, effective at such time that his successor is appointed. Mr. Schiller will continue to serve on the company's Board of Directors and, with the Board's continued recommendation of Mr. Schiller as a nominee for re-election to the Board, Mr. Schiller intends to stand for re-election at the company's 2015 annual shareholder meeting. The company also announced that Anne C. Whitaker, former President and Chief Executive Officer of Synta Pharmaceuticals, will join Valeant's Executive Management Team as Executive Vice President and Company Group Chairman.
Valeant Pharmaceuticals International, Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for Second Quarter of 2015, Full Year of 2015 and 2016
Apr 29 15
Valeant Pharmaceuticals International, Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $2,190.9 million compared to $1,886.2 million for the same period a year ago. Operating income was $543.4 million compared to $356.6 million a year ago. Income before provision for income taxes was $155.4 million compared to $4.8 million a year ago. Net profit was $74.5 million compared to net loss was $20.3 million a year ago. Net profit attributable to the company was $73.7 million or $0.22 per basic and diluted share compared to net loss attributable to the company was $22.6 million or $0.07 per basic and diluted share a year ago. Adjusted net income attributable to the company was $809.3 million compared to $599.7 million a year ago. Diluted cash earnings per share were $2.36 compared to $1.76 per share a year ago. Non GAAP basis, operating income was $486.5 million compared to $493.8 million a year ago. Income before provision for income taxes was $673.0 million compared to $612.3 million a year ago. Total adjustments to net income attributable to the company $735.6 million or $2.14 per diluted share compared to $622.3 million or $1.82 per diluted share last year. Net cash provided by operating activities was $491.1 million compared with $484.3 million a year ago. Adjusted cash flow from operations was $708.1 million compared to $636.3 million a year ago.
For the second quarter of 2015, the company expects total revenue of $2.45 billion to $2.55 billion, cash EPS $2.40 to $2.50 per share.
For the year of 2015, the company expects increasing total revenue to $10.4 billion to $10.6 billion up from $9.2 billion to $9.3 billion, expect salix revenue of $1.0 billion in 2015, increasing Cash EPS to $10.90 to $11.20 per share up from $10.10 to $10.40, expect Same Store Sales Organic Growth of 10% for the second through fourth quarters of 2015.
For the year of 2016, the company expects Accretion from Salix acquisition will be greater than 20% in 2016 and EBITDA expected to exceed $7.5 billion in 2016.
Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. Announces RELISTOR Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
Apr 24 15
April 24, 2015 Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for RELISTOR, to 11 years from the date of approval, citing the fact that RELISTOR offers a major contribution to patient care in comparison to existing therapies. The CHMP is responsible for reviewing medicinal product applications for safety, quality and efficacy. The CHMP's positive opinion on RELISTOR will be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic non-cancer pain.